DrugPatentWatch Database Preview
Patent: 5,599,673
» See Plans and Pricing
Summary for Patent: 5,599,673
Title: | Long QT syndrome genes |
Abstract: | The invention relates to the identification of the molecular basis of long QT syndrome. More specifically, the invention has identified that SCN5A and HERG cause long QT syndrome. Molecular variants of the SCN5A and HERG genes contribute to the syndrome. The analysis of these genes will provide an early diagnosis of subjects with long QT syndrome. The diagnostic methods comprise analyzing the nucleic acid sequences of the SCN5A or HERG genes of an individual to be tested and comparing them with the nucleic acid sequence of the native, nonvariant genes. Alternatively, the amino acid sequences of SCN5A or HERG may be analyzed for mutations which cause long QT syndrome. Presymptomatic diagnosis of long QT syndrome will enable practitioners to treat this disorder using existing medical therapy. |
Inventor(s): | Keating; Mark T. (Salt Lake City, UT), Curran; Mark E. (Salt Lake City, UT), Wang; Qing (Salt Lake City, UT) |
Assignee: | University of Utah Research Foundation (Salt Lake City, UT) |
Application Number: | 08/401,512 |
Patent Claims: | see list of patent claims |
Details for Patent 5,599,673
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Schering | INTRON A | interferon alfa-2b | VIAL | 103132 | 003 | 1986-06-04 | Start Trial | University of Utah Research Foundation (Salt Lake City, UT) | 2039-02-26 | RX | search | |
Schering | INTRON A | interferon alfa-2b | VIAL | 103132 | 002 | 1986-06-04 | Start Trial | University of Utah Research Foundation (Salt Lake City, UT) | 2039-02-26 | RX | search | |
Schering | INTRON A | interferon alfa-2b | VIAL | 103132 | 001 | 1986-06-04 | Start Trial | University of Utah Research Foundation (Salt Lake City, UT) | 2039-02-26 | RX | search | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 5,599,673
Country | Patent Number | Estimated Expiration |
---|---|---|
World Intellectual Property Organization (WIPO) | 9628537 | Start Trial |
European Patent Office | 0815197 | Start Trial |
Germany | 69635751 | Start Trial |
Canada | 2214646 | Start Trial |
Austria | 316133 | Start Trial |
>Country | >Patent Number | >Estimated Expiration |